Behrad Derakhshan Sells 4,600 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report) insider Behrad Derakhshan sold 4,600 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $20.01, for a total value of $92,046.00. Following the completion of the sale, the insider now directly owns 7,020 shares of the company’s stock, valued at $140,470.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Edgewise Therapeutics Stock Down 1.7 %

Shares of EWTX opened at $19.47 on Friday. Edgewise Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.69. The company has a market capitalization of $1.24 billion, a PE ratio of -13.71 and a beta of 0.16. The stock has a fifty day simple moving average of $11.78 and a two-hundred day simple moving average of $8.38.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities analysts anticipate that Edgewise Therapeutics, Inc. will post -1.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush cut their target price on Edgewise Therapeutics from $27.00 to $23.00 and set an “outperform” rating for the company in a research note on Friday, November 10th.

Read Our Latest Research Report on EWTX

Hedge Funds Weigh In On Edgewise Therapeutics

A number of hedge funds have recently modified their holdings of EWTX. JPMorgan Chase & Co. grew its holdings in shares of Edgewise Therapeutics by 23.4% during the 1st quarter. JPMorgan Chase & Co. now owns 27,166 shares of the company’s stock worth $263,000 after purchasing an additional 5,156 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Edgewise Therapeutics by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 23,355 shares of the company’s stock worth $227,000 after purchasing an additional 8,328 shares during the period. Rhumbline Advisers grew its holdings in shares of Edgewise Therapeutics by 20.8% during the 1st quarter. Rhumbline Advisers now owns 36,861 shares of the company’s stock worth $358,000 after purchasing an additional 6,350 shares during the period. BlackRock Inc. grew its holdings in shares of Edgewise Therapeutics by 0.4% during the 1st quarter. BlackRock Inc. now owns 2,055,160 shares of the company’s stock worth $19,934,000 after purchasing an additional 7,557 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Edgewise Therapeutics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 1,211,093 shares of the company’s stock worth $11,748,000 after purchasing an additional 11,693 shares during the period.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

See Also

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.